HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Adjuvant therapy of malignant melanoma].

Abstract
Malignant melanoma is resected with curative intent in 80-85% of the patients. In case of tumor thickness according to Breslow of > 4 mm and metastatic regional lymph nodes a high relapse rate and mortality of 50-90% is observed. Single agent chemotherapy with DTIC is effective as combination regimen, however does not significantly improve the relapse-free interval respectively the overall survival or quality of life. Several attempts with other adjuvant treatment modalities (e.g. BCG immunotherapy) are not convincing as well. The best results of adjuvant treatment in high-risk resected melanoma were published in 1996 by Kirkwood, who used interferon-alfa 2b. He could demonstrate a prolonged relapse free and overall survival. It does represent the current standard adjuvant treatment. However, the costs and toxicities of IFN are barriers to its widespread use.
AuthorsW Franke, N J Neumann, T Ruzicka, K W Schulte
JournalPraxis (Praxis (Bern 1994)) Vol. 90 Issue 8 Pg. 301-6 (Feb 22 2001) ISSN: 1661-8157 [Print] Switzerland
Vernacular TitleDie adjuvante Therapie des malignen Melanoms.
PMID11256332 (Publication Type: Journal Article, Review)
Chemical References
  • BCG Vaccine
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Dacarbazine
Topics
  • BCG Vaccine (therapeutic use)
  • Chemotherapy, Adjuvant
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Dacarbazine (therapeutic use)
  • Humans
  • Interferon alpha-2
  • Interferon-alpha (therapeutic use)
  • Melanoma (pathology, therapy)
  • Neoplasm Staging
  • Recombinant Proteins
  • Skin Neoplasms (pathology, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: